urlLink Entrez-PubMed : "1: Arch Neurol. 2003 Aug;60(8):1143-8.  Related Articles,  var Menu12925373 = [ ['Books','window.top.location='http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12925373&dopt=Books'','',''], ['LinkOut','window.top.location='http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12925373&dopt=ExternalLink'','',''], ['Help','window.open('/entrez/query/static/popup.html','Links_Help','resizable=no,scrollbars=yes,toolbar=no,location=no,directories=no,status=no,menubar=no,copyhistory=no,width=400,height=500');','',''] ] //--> Links    ï¿½  Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease.  Mufson EJ, Ikonomovic MD, Styren SD, Counts SE, Wuu J, Leurgans S, Bennett DA, Cochran EJ, DeKosky ST.  Department of Neurological Sciences, Rush Presbyterian-St Luke's Medical Center, 2242 W. Harrison Street, Chicago, IL 60612, USA. emufson@rush.edu  BACKGROUND: The status of nerve growth factor (NGF) levels during the prodromal phase of Alzheimer disease (AD), characterized by mild cognitive impairment (MCI), remains unknown. OBJECTIVE: To investigate whether cortical and/or hippocampal NGF levels are altered in subjects with MCI or different levels of AD severity. DESIGN AND MAIN OUTCOME MEASURES: An NGF enzyme-linked immunosorbent assay determined protein levels in the hippocampus and 5 cortical areas in people clinically diagnosed as having no cognitive impairment, MCI, mild AD, or severe AD."